Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -351.30% is 64% below its 5-year average of -213.90%, around the middle of its 5-year range (-591.98%–-32.96%).
As of the fiscal period ended Tuesday, June 30, 2026. 9.24% above its 12-month average of -387.08%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -351.30%.
RETURN ON EQUITY (ROE)
-351.30%
RETURN ON EQUITY (ROE) AVG TTM
-387.08%
RETURN ON EQUITY (ROE) AVG 3Y
-313.21%
RETURN ON EQUITY (ROE) AVG 5Y
-213.90%
RETURN ON EQUITY (ROE) AVG 10Y
-170.07%
RETURN ON EQUITY (ROE) AVG 15Y
-129.40%
RETURN ON EQUITY (ROE) AVG 20Y
-109.81%
CURRENT VS TTM AVG
+9.24%
CURRENT VS 3Y AVG
-12.16%
CURRENT VS 5Y AVG
-64.23%
CURRENT VS 10Y AVG
-106.55%
CURRENT VS 15Y AVG
-171.49%
CURRENT VS 20Y AVG
-219.92%
SECTOR MEDIAN · HEALTHCARE
-39.92%
median of 594 covered companies
CURRENT VS SECTOR MEDIAN
-779.89%
vs the sector median at left
Imunon, Inc.
Market Cap
$5.08M
Return on Equity (ROE)
-351.30%
TTM Avg
-387.08%
3Y Avg
-313.21%
5Y Avg
-213.90%
Market Cap
$5.01M
Return on Equity (ROE)
-248.66%
TTM Avg
-110.63%
3Y Avg
-33.84%
5Y Avg
-33.84%
Market Cap
$5.19M
Return on Equity (ROE)
N/A
TTM Avg
383.38%
3Y Avg
131.31%
5Y Avg
101.98%
Market Cap
$5.21M
Return on Equity (ROE)
-4165.92%
TTM Avg
61.14%
3Y Avg
-23.12%
5Y Avg
-18.15%
Market Cap
$5.22M
Return on Equity (ROE)
-156.94%
TTM Avg
-121.17%
3Y Avg
-95.34%
5Y Avg
-84.55%
Market Cap
$4.94M
Return on Equity (ROE)
-385.27%
TTM Avg
175.03%
3Y Avg
3.40%
5Y Avg
-11.76%
Market Cap
$5.24M
Return on Equity (ROE)
-225.57%
TTM Avg
-289.16%
3Y Avg
-245.03%
5Y Avg
-192.04%
Market Cap
$5.29M
Return on Equity (ROE)
-156.77%
TTM Avg
-655.11%
3Y Avg
-353.82%
5Y Avg
-293.10%
Market Cap
$5.32M
Return on Equity (ROE)
-42.05%
TTM Avg
-32.76%
3Y Avg
-25.11%
5Y Avg
-45.26%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Imunon, Inc. (IMNN) | $5.08M | -351.30% | -387.08% | -313.21% | -213.90% |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.01M | -248.66% | -110.63% | -33.84% | -33.84% |
| Lunai Bioworks Inc. (LNAI)vs › | $5.19M | N/A | 383.38% | 131.31% | 101.98% |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.21M | -4165.92% | 61.14% | -23.12% | -18.15% |
| Pulmatrix, Inc. (PULM)vs › | $5.22M | -156.94% | -121.17% | -95.34% | -84.55% |
| CalciMedica, Inc. (CALC)vs › | $4.94M | -385.27% | 175.03% | 3.40% | -11.76% |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.24M | -225.57% | -289.16% | -245.03% | -192.04% |
| Alzamend Neuro Inc (ALZN)vs › | $5.29M | -156.77% | -655.11% | -353.82% | -293.10% |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.32M | -42.05% | -32.76% | -25.11% | -45.26% |
| Lexaria Bioscience Corp. (LEXX)vs › | $4.83M | -163.18% | -235.11% | -195.15% | -161.13% |
ROE
-351.3%
ROA
-98.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -351.30% |
| 2026-03-31 | -435.81% |
| 2025-12-31 | -205.25% |
| 2025-09-30 | -351.06% |
| 2025-06-30 | -591.98% |
| 2024-12-31 | -438.71% |
| 2024-09-30 | -237.45% |
| 2024-06-30 | -483.32% |
| 2024-03-31 | -221.81% |
| 2023-12-31 | -145.77% |
| 2023-09-30 | -154.16% |
| 2023-06-30 | -141.91% |
| 2023-03-31 | -116.39% |
| 2022-12-31 | -122.40% |
| 2022-09-30 | -65.02% |
| 2022-06-30 | -55.59% |
| 2022-03-31 | -55.23% |
| 2021-12-31 | -37.22% |
| 2021-09-30 | -32.96% |
| 2021-06-30 | -34.69% |
| 2021-03-31 | -40.24% |
| 2020-12-31 | -115.43% |
| 2020-09-30 | -115.62% |
| 2020-06-30 | -78.40% |
| 2020-03-31 | -120.56% |
| 2019-12-31 | -115.75% |
| 2019-09-30 | -53.48% |
| 2019-06-30 | -39.55% |
| 2019-03-31 | -45.68% |
| 2018-12-31 | -56.96% |
| 2018-09-30 | -145.69% |
| 2018-06-30 | -120.43% |
| 2018-03-31 | -83.52% |
| 2017-12-31 | -76.40% |
| 2017-09-30 | -399.43% |
| 2017-06-30 | -328.73% |
| 2017-03-31 | -352.06% |
| 2016-12-31 | -327.90% |
| 2016-09-30 | -209.71% |
| 2016-06-30 | -121.30% |
| 2016-03-31 | -138.30% |
| 2015-12-31 | -110.18% |
| 2015-09-30 | -93.30% |
| 2015-06-30 | -89.60% |
| 2015-03-31 | -101.40% |
| 2014-12-31 | -77.67% |
| 2014-09-30 | -59.07% |
| 2014-06-30 | -44.35% |
| 2014-03-31 | -32.11% |
| 2013-12-31 | -26.17% |
| 2013-09-30 | -43.10% |
| 2013-06-30 | -43.98% |
| 2013-03-31 | -65.12% |
| 2012-12-31 | -222.11% |
| 2012-09-30 | -187.58% |
| 2012-06-30 | -170.17% |
| 2012-03-31 | -125.95% |
| 2011-12-31 | -88.66% |
| 2011-09-30 | -122.85% |
| 2010-06-30 | -742.91% |
| 2010-03-31 | -402.27% |
| 2009-12-31 | -151.42% |
| 2009-09-30 | -115.13% |
| 2009-06-30 | -115.85% |
| 2009-03-31 | -68.99% |
| 2008-12-31 | -59.75% |
| 2008-09-30 | -67.13% |
| 2008-06-30 | -52.76% |
| 2008-03-31 | 125.18% |
| 2007-12-31 | 115.33% |
| 2007-09-30 | 103.58% |
| 2007-06-30 | 101.72% |
| 2006-03-31 | -401.04% |
| 2005-12-31 | -253.55% |
| 2005-09-30 | -177.04% |
| 2005-06-30 | -148.75% |
| 2005-03-31 | -102.99% |
| 2004-12-31 | -116.83% |
| 2004-09-30 | -91.64% |
| 2004-06-30 | -77.49% |
| 2004-03-31 | -85.90% |
| 2003-12-31 | -106.24% |
| 2003-09-30 | -98.67% |
| 2003-06-30 | -183.75% |
